Lacydyna

Lacidipine, the active ingredient in Lacydyna, is a calcium channel blocker presented as an oral tablet for oral use. It works by relaxing vascular smooth muscle, thereby reducing peripheral resistance and lowering blood pressure in adult patients diagnosed with hypertension. The medication is intended for chronic management of high blood pressure under medical supervision.

GNH USA supplies Lacydyna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for healthcare providers and ensures product quality through stringent quality control.

Lacidipine is used to treat hypertension, a condition characterized by elevated arterial pressure. Essential hypertension: reduces both systolic and diastolic blood pressure, improving cardiovascular risk profile in patients with primary high blood pressure. Secondary hypertension: assists in controlling blood pressure when the condition is driven by renal, endocrine or vascular disorders, complementing treatment of the underlying cause. Isolated systolic hypertension: effectively lowers elevated systolic pressure, particularly in elderly patients, contributing to reduced risk of stroke and heart disease.

Lacidipine may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Headache: mild to moderate headache often occurring during initial therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headed sensation, especially when standing quickly. Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Allergic reactions: rash, itching, or anaphylaxis requiring immediate medical attention.

When prescribing Lacidipine, clinicians should consider several safety precautions to minimize risk. - Blood pressure monitoring: regularly assess blood pressure to ensure therapeutic response and avoid excessive hypotension. - Hepatic impairment: use with caution in patients with liver dysfunction, as metabolism may be reduced. - Elderly patients: start at lower dose and monitor for dizziness or falls. - Concomitant antihypertensives: avoid additive hypotensive effects by adjusting doses of other blood pressure medicines. - Pregnancy and lactation: contraindicated unless clearly needed; discuss risks with obstetric specialist. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lacidipine plasma levels, raising risk of hypotension. - Grapefruit juice: can markedly raise drug concentration, leading to enhanced blood pressure lowering. - Co‑administration with other potent vasodilators: may cause severe hypotension. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Lacidipine effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Diuretics: may increase risk of electrolyte imbalance and excessive blood pressure reduction.